COST-EFFECTIVENESS ANALYSIS OF THE ORIGINATOR RECOMBINANT HUMAN FOLLICLE-STIMULATING HORMONE (R-HFSH) AND URINARY HIGHLY PURIFIED MENOPAUSAL GONADOTROPIN (HMG) BASED ON DATA FROM A LARGE GERMAN REGISTRY